XLO - Xilio Therapeutics, Inc.
IEX Last Trade
1.05
0 0%
Share volume: 100
Last Updated: Fri 10 Jan 2025 06:05:07 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.49%
PREVIOUS CLOSE
CHG
CHG%
$1.05
0.00
0.00%
Fundamental analysis
6%
Profitability
0%
Dept financing
36%
Liquidity
24%
Performance
0%
Performance
5 Days
-1.79%
1 Month
13.54%
3 Months
41.75%
6 Months
8.91%
1 Year
61.12%
2 Year
-58.65%
Key data
Stock price
$1.05
DAY RANGE
$1.05 - $1.05
52 WEEK RANGE
$0.59 - $1.93
52 WEEK CHANGE
$61.12
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: René Russo
Region: US
Website: xiliotx.com
Employees: 70
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: xiliotx.com
Employees: 70
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Xilio Therapeutics, Inc. develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate.
Recent news